Neluptin (Tianeptine Sodium)

Tianeptine Sodium, the active ingredient in Neluptin, is an atypical antidepressant presented as an oral formulation for systemic use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional capacity.

GNH USA supplies Neluptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Customers benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process.

Tianeptine Sodium is employed in the management of depressive disorders and related conditions. - Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Dysthymic disorder: provides sustained relief of chronic low‑grade depressive mood. - Anxiety associated with depression: alleviates anxiety symptoms that coexist with depressive episodes.

Tianeptine Sodium may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Dry mouth: reduced salivary flow. - Constipation: decreased bowel movements. - Dizziness: sensation of light‑headedness. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Seizures: convulsive episodes. - Cardiovascular events: arrhythmia or myocardial infarction.

When prescribing Tianeptine Sodium, clinicians should consider several precautionary measures to ensure safe use. - Hepatic assessment: evaluate liver function before initiating therapy. - Mood monitoring: observe for worsening depression or emergence of suicidal thoughts. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Substance misuse: use with caution in patients with a history of drug dependence. - Concomitant CNS depressants: monitor for additive sedation. - Pregnancy and lactation: assess risk‑benefit ratio as safety data are limited. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Tianeptine Sodium can interact with other medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin‑related toxicity. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: potential for serotonin syndrome. - Alcohol: may enhance central nervous system depression. - Benzodiazepines: increased sedative effect. - Opioids: heightened risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): possible alteration of bleeding risk. - CYP450 substrates (e.g., CYP2D6 metabolized drugs): may affect plasma concentrations. - Antihypertensives: additive blood pressure lowering. - Anticonvulsants: potential impact on seizure threshold. - Herbal supplements (e.g., St. John’s wort): may modify serotonergic activity.